The correction of lipid metabolism and markers of inflammation by diet and hmg-coa reductase inhibitors in patients with a different forms of hyperlipidemia

Authors

  • O. A. Golubeva FGU RKNPK MH and SR RF
  • M. G. Tvorogova FGBU MZiSR RF; FSBI GNITsPM MZiSR RF
  • P. P. Malyshev FGBU MZiSR RF; FSBI GNITsPM MZiSR RF
  • T. A. Rozhkova FGBU MZiSR RF; FSBI GNITsPM MZiSR RF
  • V. V. Kukharchuk FGBU MZiSR RF; FSBI GNITsPM MZiSR RF

Keywords:

coronary heart disease, lovastatin, family hyperlipidemia, triglycerides

Abstract

Familial combined hyperlipidemia (SCHF) is one of the most common forms of primary hyperlipoproteinemia (HFH). The term familial combined hyperlipidemia (FCH) was first coined by Goldstein J.L. et al. in 1973 to characterize a hereditary disorder of lipid metabolism, in which the proband and his relatives of the 1st degree of kinship had different types of HLP: IIA, IIB, IV and V [1]. The frequency of SCHF in the general population is 0.5-2%, and among patients under the age of 60 years with coronary heart disease (IHD) it is significantly higher - 15-20%

Downloads

Download data is not yet available.

Downloads

Published

2012-03-28

How to Cite

Golubeva O. A., Tvorogova M. G., Malyshev P. P., Rozhkova T. A., Kukharchuk V. V. The correction of lipid metabolism and markers of inflammation by diet and hmg-coa reductase inhibitors in patients with a different forms of hyperlipidemia // The Journal of Atherosclerosis and Dyslipidemias. 2012. VOL. № 1 (6). PP. 16–21.

Issue

No. 1 (6) (2012)

Section

Original research paper